

Sexually Transmitted Disease Surveillance January–July 2024: Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles

**Division of STD Prevention
September 2025**

NOTE: The Enhanced Gonococcal Isolate Surveillance Project (eGISP) ended on July 31, 2024. On August 1, 2024, CDC began the Combatting Antimicrobial Resistant Gonorrhea and Other STIs (CARGOS) project. The activities conducted under eGISP were incorporated into CARGOS and any antimicrobial resistant gonorrhea data collected after August 1, 2024 will be reported in CARGOS Profiles.

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION
DIVISION OF STD PREVENTION
ATLANTA, GEORGIA 30329-4027**

Acknowledgments

2

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Rebekah Frankson, Kristen Kreisel, Emily Rowlinson, and Luke Shouse, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Matthew Schmerer, Myriam Bèlanger, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, and LaShondra Berman and Eboni Galloway, Behavioral Science and Epidemiology Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance January-July 2024: Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles*. Atlanta: U.S. Department of Health and Human Services; 2025.

Web Site

The online version of this report is available at <https://www.cdc.gov/sti-statistics/qisp-profiles/>.

Technical Note

Antimicrobial susceptibility data presented in this report are based on criteria established by the Clinical & Laboratory Standards Institute (CLSI) and the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria (FDA-STIC).

2024 Enhanced Gonococcal Isolate Surveillance Project
Clinical Sites and Years Participated

Columbus, Ohio (2018-2019, 2023-2024)	Orange County, California (2018–2024)
Honolulu, Hawaii (2023-2024)	Philadelphia, Pennsylvania (2018–2024)
Las Vegas, Nevada (2018–2024)	Phoenix, Arizona (2020–2024)
Minneapolis, Minnesota (2018–2019, 2023-2024)	San Diego, California (2018–2024)
New Orleans, Louisiana (2018–2024)	

2024 Enhanced Gonococcal Isolate Surveillance Project Regional Laboratories

Maryland Department of Health and Mental Hygiene <i>Baltimore, Maryland</i>
Tennessee Department of Health <i>Nashville, Tennessee</i>
Utah Department of Health <i>Salt Lake City, Utah</i>
Washington State Department of Health <i>Seattle, Washington</i>

2024 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles
Table of Contents

Columbus, Ohio	6-10
Honolulu, Hawaii	11-15
Las Vegas, Nevada	16-23
Minneapolis, Minnesota	24-28
New Orleans, Louisiana	29-36
Orange County, California	37-44
Philadelphia, Pennsylvania	45-52
Phoenix, Arizona	53-60
San Diego, California	61-68

2024 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles
List of Tables

For each participating site of the 2024 Gonococcal Isolate Surveillance Project, the following tables are presented:

Table A.	Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1-July 31, 2024
Table B.	Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1-July 31, 2024
Table C.	Number of <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table D.	Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table E.	Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table F.	Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table G.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table H.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table I.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024
Table J.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), January 1, 2022-July 31, 2024

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0.0)	2 (14.3)	2 (14.3)	5 (35.7)	0 (0.0)	1 (7.1)	0 (0.0)	1 (7.1)	1 (7.1)	2 (14.3)	0 (0.0)	14
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	0 (0.0)	11 (78.6)	0 (0.0)	0 (0.0)	0 (0.0)	3 (21.4)	0 (0.0)	14
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	*	*	*	*
Genital	2023	9	36	0	45
Genital	2024	4	10	0	14
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0	0	0	0
Pharyngeal	2024	0	0	0	0
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0
Rectal	2024	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	40 (88.9)	4 (8.9)	0 (0.0)	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	45
Genital	2024	14 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	39 (86.7)	6 (13.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	45
Genital	2024	13 (92.9)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	9 (20.0)	29 (64.4)	2 (4.4)	4 (8.9)	0 (0.0)	0 (0.0)	1 (2.2)	0 (0.0)	45
Genital	2024	1 (7.1)	10 (71.4)	0 (0.0)	2 (14.3)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	0 / 36 (0.0)	0 / 0 (0.0)	0 / 45 (0.0)
Genital	2024	0 / 4 (0.0)	0 / 10 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	0 / 36 (0.0)	0 / 0 (0.0)	0 / 45 (0.0)
Genital	2024	0 / 4 (0.0)	0 / 10 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	1 / 36 (2.8)	0 / 0 (0.0)	1 / 45 (2.2)
Genital	2024	0 / 4 (0.0)	1 / 10 (10.0)	0 / 0 (0.0)	1 / 14 (7.1)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	4 / 9 (44.4)	14 / 36 (38.9)	0 / 0 (0.0)	18 / 45 (40.0)
Genital	2024	1 / 4 (25.0)	0 / 10 (0.0)	0 / 0 (0.0)	1 / 14 (7.1)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0.0)	11 (33.3)	2 (6.1)	3 (9.1)	7 (21.2)	3 (9.1)	1 (3.0)	2 (6.1)	1 (3.0)	1 (3.0)	2 (6.1)	33
Genital	Female	0 (0.0)	3 (60.0)	1 (20.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	Male	2 (25.0)	3 (37.5)	2 (25.0)	0 (0.0)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	Female	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	Male	1 (11.1)	4 (44.4)	1 (11.1)	2 (22.2)	0 (0.0)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	9
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	4 (12.1)	5 (15.2)	5 (15.2)	8 (24.2)	5 (15.2)	5 (15.2)	1 (3.0)	33
Genital	Female	0 (0.0)	3 (60.0)	1 (20.0)	0 (0.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	Male	0 (0.0)	7 (87.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)	0 (0.0)	8
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	2
Rectal	Male	0 (0.0)	5 (55.6)	1 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	3 (33.3)	0 (0.0)	9
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	*	*	*	*
Genital	2023	11	11	0	22
Genital	2024	10	22	5	37
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	2	0	0	2
Pharyngeal	2024	8	0	2	10
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0
Rectal	2024	7	0	0	7

MSM = Men who have sex with men; MSW = Men who have sex with women only.

* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	15 (62.5)	4 (16.7)	1 (4.2)	1 (4.2)	2 (8.3)	0 (0.0)	0 (0.0)	1 (4.2)	24
Genital	2024	29 (76.3)	3 (7.9)	1 (2.6)	4 (10.5)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	38
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2024	9 (90.0)	0 (0.0)	0 (0.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	8 (80.0)	1 (10.0)	0 (0.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	14 (58.3)	6 (25.0)	1 (4.2)	2 (8.3)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)	24
Genital	2024	25 (65.8)	8 (21.1)	4 (10.5)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	38
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2024	8 (80.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	8 (80.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	6 (25.0)	7 (29.2)	4 (16.7)	7 (29.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24
Genital	2024	6 (15.8)	20 (52.6)	1 (2.6)	6 (15.8)	5 (13.2)	0 (0.0)	0 (0.0)	0 (0.0)	38
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	1 (50.0)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2024	0 (0.0)	3 (30.0)	1 (10.0)	5 (50.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	1 (10.0)	5 (50.0)	0 (0.0)	4 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	3 / 11 (27.3)	0 / 0 (0.0)	3 / 22 (13.6)
Genital	2024	0 / 10 (0.0)	1 / 22 (4.5)	0 / 5 (0.0)	1 / 37 (2.7)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2024	0 / 8 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 10 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 7 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 7 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	1 / 11 (9.1)	0 / 0 (0.0)	1 / 22 (4.5)
Genital	2024	0 / 10 (0.0)	0 / 22 (0.0)	0 / 5 (0.0)	0 / 37 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2024	0 / 8 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 10 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 7 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 7 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 22 (0.0)
Genital	2024	1 / 10 (10.0)	4 / 22 (18.2)	0 / 5 (0.0)	5 / 37 (13.5)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2024	1 / 8 (12.5)	0 / 0 (0.0)	0 / 2 (0.0)	1 / 10 (10.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 7 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 7 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	6 / 11 (54.5)	8 / 11 (72.7)	0 / 0 (0.0)	14 / 22 (63.6)
Genital	2024	4 / 10 (40.0)	9 / 22 (40.9)	2 / 5 (40.0)	15 / 37 (40.5)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	2 / 2 (100.0)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 2 (100.0)
Pharyngeal	2024	7 / 8 (87.5)	0 / 0 (0.0)	1 / 2 (50.0)	8 / 10 (80.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	4 / 7 (57.1)	0 / 0 (0.0)	0 / 0 (0.0)	4 / 7 (57.1)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	6 (12.0)	9 (18.0)	4 (8.0)	8 (16.0)	4 (8.0)	12 (24.0)	1 (2.0)	2 (4.0)	3 (6.0)	0 (0.0)	1 (2.0)	50
Genital	Female	1 (33.3)	1 (33.3)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	Male	1 (8.3)	2 (16.7)	1 (8.3)	3 (25.0)	2 (16.7)	1 (8.3)	1 (8.3)	0 (0.0)	1 (8.3)	0 (0.0)	0 (0.0)	12
Pharyngeal	Female	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	Male	1 (12.5)	2 (25.0)	2 (25.0)	2 (25.0)	0 (0.0)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Rectal	Female	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	1 (2.0)	0 (0.0)	21 (42.0)	0 (0.0)	6 (12.0)	19 (38.0)	0 (0.0)	3 (6.0)	50
Genital	Female	0 (0.0)	0 (0.0)	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	Male	0 (0.0)	1 (8.3)	5 (41.7)	0 (0.0)	0 (0.0)	5 (41.7)	0 (0.0)	1 (8.3)	12
Pharyngeal	Female	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	2
Rectal	Male	0 (0.0)	0 (0.0)	1 (12.5)	0 (0.0)	3 (37.5)	4 (50.0)	0 (0.0)	0 (0.0)	8
Rectal	Female	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.

AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	47	129	0	176
Genital	2023	53	90	4	147
Genital	2024	16	34	3	53
Pharyngeal	2022	14	9	2	25
Pharyngeal	2023	20	10	7	37
Pharyngeal	2024	7	5	2	14
Rectal	2022	21	0	1	22
Rectal	2023	29	0	0	29
Rectal	2024	8	0	2	10

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	116 (65.5)	49 (27.7)	5 (2.8)	7 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Genital	2023	94 (63.1)	27 (18.1)	10 (6.7)	18 (12.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	149
Genital	2024	33 (62.3)	9 (17.0)	4 (7.5)	6 (11.3)	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	53
Pharyngeal	2022	12 (48.0)	8 (32.0)	3 (12.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Pharyngeal	2023	22 (59.5)	6 (16.2)	4 (10.8)	4 (10.8)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	37
Pharyngeal	2024	10 (66.7)	1 (6.7)	1 (6.7)	3 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Rectal	2022	15 (65.2)	7 (30.4)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	21 (70.0)	3 (10.0)	4 (13.3)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30
Rectal	2024	6 (60.0)	1 (10.0)	2 (20.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	120 (67.8)	54 (30.5)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Genital	2023	76 (51.0)	48 (32.2)	25 (16.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	149
Genital	2024	25 (47.2)	20 (37.7)	6 (11.3)	1 (1.9)	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	53
Pharyngeal	2022	17 (68.0)	6 (24.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Pharyngeal	2023	17 (45.9)	14 (37.8)	6 (16.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	37
Pharyngeal	2024	7 (46.7)	8 (53.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Rectal	2022	17 (73.9)	5 (21.7)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	15 (50.0)	10 (33.3)	5 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30
Rectal	2024	3 (30.0)	5 (50.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	38 (21.5)	88 (49.7)	19 (10.7)	30 (16.9)	1 (0.6)	0 (0.0)	1 (0.6)	0 (0.0)	177
Genital	2023	17 (11.4)	84 (56.4)	16 (10.7)	22 (14.8)	10 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	149
Genital	2024	15 (28.3)	22 (41.5)	3 (5.7)	9 (17.0)	3 (5.7)	0 (0.0)	0 (0.0)	1 (1.9)	53
Pharyngeal	2022	4 (16.0)	8 (32.0)	3 (12.0)	9 (36.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	25
Pharyngeal	2023	5 (13.5)	16 (43.2)	7 (18.9)	6 (16.2)	3 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)	37
Pharyngeal	2024	1 (6.7)	9 (60.0)	2 (13.3)	2 (13.3)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	15
Rectal	2022	1 (4.3)	11 (47.8)	5 (21.7)	6 (26.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	2 (6.7)	14 (46.7)	9 (30.0)	4 (13.3)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	30
Rectal	2024	0 (0.0)	5 (50.0)	4 (40.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 47 (0.0)	0 / 129 (0.0)	0 / 0 (0.0)	0 / 176 (0.0)
Genital	2023	0 / 53 (0.0)	0 / 90 (0.0)	0 / 4 (0.0)	0 / 147 (0.0)
Genital	2024	0 / 16 (0.0)	1 / 34 (2.9)	0 / 3 (0.0)	1 / 53 (1.9)
Pharyngeal	2022	0 / 14 (0.0)	0 / 9 (0.0)	0 / 2 (0.0)	0 / 25 (0.0)
Pharyngeal	2023	1 / 20 (5.0)	0 / 10 (0.0)	0 / 7 (0.0)	1 / 37 (2.7)
Pharyngeal	2024	0 / 7 (0.0)	0 / 5 (0.0)	0 / 2 (0.0)	0 / 14 (0.0)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	0 / 29 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)
Rectal	2024	0 / 8 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 10 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 47 (0.0)	0 / 129 (0.0)	0 / 0 (0.0)	0 / 176 (0.0)
Genital	2023	0 / 53 (0.0)	0 / 90 (0.0)	0 / 4 (0.0)	0 / 147 (0.0)
Genital	2024	1 / 16 (6.3)	0 / 34 (0.0)	0 / 3 (0.0)	1 / 53 (1.9)
Pharyngeal	2022	0 / 14 (0.0)	0 / 9 (0.0)	0 / 2 (0.0)	0 / 25 (0.0)
Pharyngeal	2023	0 / 20 (0.0)	0 / 10 (0.0)	0 / 7 (0.0)	0 / 37 (0.0)
Pharyngeal	2024	0 / 7 (0.0)	0 / 5 (0.0)	0 / 2 (0.0)	0 / 14 (0.0)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	0 / 29 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)
Rectal	2024	0 / 8 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 10 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	1 / 47 (2.1)	1 / 129 (0.8)	0 / 0 (0.0)	2 / 176 (1.1)
Genital	2023	3 / 53 (5.7)	7 / 90 (7.8)	0 / 4 (0.0)	10 / 147 (6.8)
Genital	2024	1 / 16 (6.3)	3 / 34 (8.8)	0 / 3 (0.0)	4 / 53 (7.5)
Pharyngeal	2022	1 / 14 (7.1)	0 / 9 (0.0)	0 / 2 (0.0)	1 / 25 (4.0)
Pharyngeal	2023	2 / 20 (10.0)	0 / 10 (0.0)	1 / 7 (14.3)	3 / 37 (8.1)
Pharyngeal	2024	1 / 7 (14.3)	0 / 5 (0.0)	0 / 2 (0.0)	1 / 14 (7.1)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	1 / 29 (3.4)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 29 (3.4)
Rectal	2024	0 / 8 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 10 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	22 / 47 (46.8)	28 / 129 (21.7)	0 / 0 (0.0)	50 / 176 (28.4)
Genital	2023	29 / 53 (54.7)	25 / 90 (27.8)	2 / 4 (50.0)	56 / 147 (38.1)
Genital	2024	9 / 16 (56.3)	15 / 34 (44.1)	1 / 3 (33.3)	25 / 53 (47.2)
Pharyngeal	2022	8 / 14 (57.1)	0 / 9 (0.0)	1 / 2 (50.0)	9 / 25 (36.0)
Pharyngeal	2023	10 / 20 (50.0)	2 / 10 (20.0)	3 / 7 (42.9)	15 / 37 (40.5)
Pharyngeal	2024	4 / 7 (57.1)	2 / 5 (40.0)	0 / 2 (0.0)	6 / 14 (42.9)
Rectal	2022	4 / 21 (19.0)	0 / 0 (0.0)	1 / 1 (100.0)	5 / 22 (22.7)
Rectal	2023	11 / 29 (37.9)	0 / 0 (0.0)	0 / 0 (0.0)	11 / 29 (37.9)
Rectal	2024	3 / 8 (37.5)	0 / 0 (0.0)	0 / 2 (0.0)	3 / 10 (30.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	3 (7.3)	3 (7.3)	4 (9.8)	9 (22.0)	8 (19.5)	3 (7.3)	6 (14.6)	1 (2.4)	2 (4.9)	1 (2.4)	1 (2.4)	41
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	2 (4.9)	1 (2.4)	23 (56.1)	0 (0.0)	8 (19.5)	5 (12.2)	2 (4.9)	0 (0.0)	41
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	*	*	*	*
Genital	2023	16	30	0	46
Genital	2024	10	29	0	39
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0	0	0	0
Pharyngeal	2024	0	0	0	0
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0
Rectal	2024	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	40 (81.6)	7 (14.3)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Genital	2024	39 (95.1)	1 (2.4)	0 (0.0)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	41 (83.7)	6 (12.2)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Genital	2024	37 (90.2)	4 (9.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	7 (14.3)	35 (71.4)	2 (4.1)	5 (10.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Genital	2024	5 (12.2)	30 (73.2)	3 (7.3)	2 (4.9)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	41
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Genital	2024	0 / 10 (0.0)	0 / 29 (0.0)	0 / 0 (0.0)	0 / 39 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Genital	2024	0 / 10 (0.0)	0 / 29 (0.0)	0 / 0 (0.0)	0 / 39 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Genital	2024	0 / 10 (0.0)	0 / 29 (0.0)	0 / 0 (0.0)	0 / 39 (0.0)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	*	*	*	*
Genital	2023	6 / 16 (37.5)	5 / 30 (16.7)	0 / 0 (0.0)	11 / 46 (23.9)
Genital	2024	3 / 10 (30.0)	5 / 29 (17.2)	0 / 0 (0.0)	8 / 39 (20.5)
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0.0)	1 (3.4)	5 (17.2)	6 (20.7)	11 (37.9)	1 (3.4)	1 (3.4)	2 (6.9)	0 (0.0)	1 (3.4)	1 (3.4)	29
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	2 (50.0)	0 (0.0)	1 (25.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	0 (0.0)	21 (72.4)	0 (0.0)	6 (20.7)	1 (3.4)	1 (3.4)	0 (0.0)	29
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	3 (75.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.

AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	42	24	0	66
Genital	2023	57	27	0	84
Genital	2024	10	19	0	29
Pharyngeal	2022	7	3	0	10
Pharyngeal	2023	14	0	0	14
Pharyngeal	2024	4	0	0	4
Rectal	2022	9	0	0	9
Rectal	2023	2	0	0	2
Rectal	2024	2	0	0	2

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	48 (68.6)	12 (17.1)	6 (8.6)	4 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Genital	2023	50 (59.5)	14 (16.7)	2 (2.4)	17 (20.2)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	84
Genital	2024	21 (72.4)	6 (20.7)	1 (3.4)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	29
Pharyngeal	2022	8 (80.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Pharyngeal	2023	9 (64.3)	0 (0.0)	1 (7.1)	4 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2024	2 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	4 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	43 (61.4)	25 (35.7)	2 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Genital	2023	54 (64.3)	21 (25.0)	9 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	84
Genital	2024	21 (72.4)	5 (17.2)	3 (10.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	29
Pharyngeal	2022	7 (70.0)	3 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Pharyngeal	2023	6 (42.9)	5 (35.7)	3 (21.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2024	3 (75.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	3 (30.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2023	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	13 (18.6)	31 (44.3)	13 (18.6)	8 (11.4)	4 (5.7)	1 (1.4)	0 (0.0)	0 (0.0)	70
Genital	2023	15 (17.9)	47 (56.0)	8 (9.5)	8 (9.5)	6 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	84
Genital	2024	2 (6.9)	25 (86.2)	0 (0.0)	1 (3.4)	1 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	29
Pharyngeal	2022	3 (30.0)	3 (30.0)	0 (0.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (20.0)	10
Pharyngeal	2023	1 (7.1)	5 (35.7)	2 (14.3)	4 (28.6)	1 (7.1)	0 (0.0)	0 (0.0)	1 (7.1)	14
Pharyngeal	2024	0 (0.0)	3 (75.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	1 (10.0)	4 (40.0)	1 (10.0)	1 (10.0)	1 (10.0)	0 (0.0)	0 (0.0)	2 (20.0)	10
Rectal	2023	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 42 (0.0)	0 / 24 (0.0)	0 / 0 (0.0)	0 / 66 (0.0)
Genital	2023	1 / 57 (1.8)	0 / 27 (0.0)	0 / 0 (0.0)	1 / 84 (1.2)
Genital	2024	0 / 10 (0.0)	0 / 19 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)
Pharyngeal	2022	0 / 7 (0.0)	0 / 3 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Pharyngeal	2024	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	0 / 9 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 9 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 42 (0.0)	0 / 24 (0.0)	0 / 0 (0.0)	0 / 66 (0.0)
Genital	2023	0 / 57 (0.0)	0 / 27 (0.0)	0 / 0 (0.0)	0 / 84 (0.0)
Genital	2024	0 / 10 (0.0)	0 / 19 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)
Pharyngeal	2022	0 / 7 (0.0)	0 / 3 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Pharyngeal	2024	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	0 / 9 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 9 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	4 / 42 (9.5)	1 / 24 (4.2)	0 / 0 (0.0)	5 / 66 (7.6)
Genital	2023	6 / 57 (10.5)	0 / 27 (0.0)	0 / 0 (0.0)	6 / 84 (7.1)
Genital	2024	1 / 10 (10.0)	0 / 19 (0.0)	0 / 0 (0.0)	1 / 29 (3.4)
Pharyngeal	2022	2 / 7 (28.6)	0 / 3 (0.0)	0 / 0 (0.0)	2 / 10 (20.0)
Pharyngeal	2023	2 / 14 (14.3)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 14 (14.3)
Pharyngeal	2024	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	3 / 9 (33.3)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 9 (33.3)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	14 / 42 (33.3)	10 / 24 (41.7)	0 / 0 (0.0)	24 / 66 (36.4)
Genital	2023	24 / 57 (42.1)	12 / 27 (44.4)	0 / 0 (0.0)	36 / 84 (42.9)
Genital	2024	4 / 10 (40.0)	2 / 19 (10.5)	0 / 0 (0.0)	6 / 29 (20.7)
Pharyngeal	2022	4 / 7 (57.1)	0 / 3 (0.0)	0 / 0 (0.0)	4 / 10 (40.0)
Pharyngeal	2023	9 / 14 (64.3)	0 / 0 (0.0)	0 / 0 (0.0)	9 / 14 (64.3)
Pharyngeal	2024	3 / 4 (75.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 4 (75.0)
Rectal	2022	4 / 9 (44.4)	0 / 0 (0.0)	0 / 0 (0.0)	4 / 9 (44.4)
Rectal	2023	1 / 2 (50.0)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 2 (50.0)
Rectal	2024	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	1 (1.9)	4 (7.4)	11 (20.4)	12 (22.2)	10 (18.5)	9 (16.7)	4 (7.4)	2 (3.7)	0 (0.0)	1 (1.9)	0 (0.0)	54
Genital	Female	0 (0.0)	2 (28.6)	1 (14.3)	0 (0.0)	3 (42.9)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7
Pharyngeal	Male	1 (2.3)	8 (18.6)	15 (34.9)	9 (20.9)	5 (11.6)	3 (7.0)	1 (2.3)	1 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	43
Pharyngeal	Female	1 (20.0)	1 (20.0)	1 (20.0)	0 (0.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Rectal	Male	2 (3.7)	6 (11.1)	17 (31.5)	13 (24.1)	5 (9.3)	2 (3.7)	3 (5.6)	3 (5.6)	3 (5.6)	0 (0.0)	0 (0.0)	54
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	8 (14.8)	0 (0.0)	0 (0.0)	4 (7.4)	33 (61.1)	0 (0.0)	9 (16.7)	54
Genital	Female	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	6 (85.7)	0 (0.0)	0 (0.0)	7
Pharyngeal	Male	0 (0.0)	6 (14.0)	0 (0.0)	0 (0.0)	3 (7.0)	29 (67.4)	0 (0.0)	5 (11.6)	43
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)	3 (60.0)	0 (0.0)	0 (0.0)	5
Rectal	Male	0 (0.0)	10 (18.5)	0 (0.0)	0 (0.0)	4 (7.4)	38 (70.4)	0 (0.0)	2 (3.7)	54
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	72	44	13	129
Genital	2023	71	37	5	113
Genital	2024	29	19	6	54
Pharyngeal	2022	58	3	7	68
Pharyngeal	2023	56	5	3	64
Pharyngeal	2024	39	1	5	45
Rectal	2022	93	3	4	100
Rectal	2023	84	0	2	86
Rectal	2024	45	2	0	47

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	84 (64.6)	34 (26.2)	5 (3.8)	7 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	130
Genital	2023	86 (62.3)	28 (20.3)	9 (6.5)	15 (10.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	138
Genital	2024	35 (57.4)	5 (8.2)	9 (14.8)	12 (19.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	61
Pharyngeal	2022	39 (51.3)	25 (32.9)	3 (3.9)	9 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	76
Pharyngeal	2023	48 (57.8)	25 (30.1)	8 (9.6)	2 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	83
Pharyngeal	2024	29 (56.9)	7 (13.7)	5 (9.8)	9 (17.6)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	49 (44.1)	37 (33.3)	8 (7.2)	17 (15.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	69 (61.1)	25 (22.1)	10 (8.8)	9 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2024	39 (66.1)	4 (6.8)	7 (11.9)	9 (15.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	59

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	79 (60.8)	42 (32.3)	9 (6.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	130
Genital	2023	83 (60.1)	43 (31.2)	12 (8.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	138
Genital	2024	32 (52.5)	20 (32.8)	9 (14.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	61
Pharyngeal	2022	43 (56.6)	30 (39.5)	3 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	76
Pharyngeal	2023	43 (51.8)	34 (41.0)	6 (7.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	83
Pharyngeal	2024	27 (52.9)	18 (35.3)	6 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	50 (45.0)	52 (46.8)	9 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	65 (57.5)	40 (35.4)	8 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2024	39 (66.1)	15 (25.4)	5 (8.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	59

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	14 (10.8)	84 (64.6)	11 (8.5)	7 (5.4)	13 (10.0)	0 (0.0)	0 (0.0)	1 (0.8)	130
Genital	2023	21 (15.2)	70 (50.7)	21 (15.2)	12 (8.7)	13 (9.4)	0 (0.0)	0 (0.0)	1 (0.7)	138
Genital	2024	5 (8.2)	44 (72.1)	3 (4.9)	4 (6.6)	5 (8.2)	0 (0.0)	0 (0.0)	0 (0.0)	61
Pharyngeal	2022	7 (9.2)	49 (64.5)	8 (10.5)	6 (7.9)	5 (6.6)	0 (0.0)	0 (0.0)	1 (1.3)	76
Pharyngeal	2023	5 (6.0)	49 (59.0)	7 (8.4)	13 (15.7)	8 (9.6)	0 (0.0)	0 (0.0)	1 (1.2)	83
Pharyngeal	2024	5 (9.8)	29 (56.9)	3 (5.9)	8 (15.7)	6 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	12 (10.8)	66 (59.5)	7 (6.3)	15 (13.5)	11 (9.9)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	8 (7.1)	69 (61.1)	16 (14.2)	8 (7.1)	11 (9.7)	0 (0.0)	0 (0.0)	1 (0.9)	113
Rectal	2024	5 (8.5)	36 (61.0)	4 (6.8)	8 (13.6)	6 (10.2)	0 (0.0)	0 (0.0)	0 (0.0)	59

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 72 (0.0)	0 / 44 (0.0)	0 / 13 (0.0)	0 / 129 (0.0)
Genital	2023	0 / 71 (0.0)	0 / 37 (0.0)	0 / 5 (0.0)	0 / 113 (0.0)
Genital	2024	0 / 29 (0.0)	0 / 19 (0.0)	0 / 6 (0.0)	0 / 54 (0.0)
Pharyngeal	2022	0 / 58 (0.0)	0 / 3 (0.0)	0 / 7 (0.0)	0 / 68 (0.0)
Pharyngeal	2023	0 / 56 (0.0)	0 / 5 (0.0)	0 / 3 (0.0)	0 / 64 (0.0)
Pharyngeal	2024	1 / 39 (2.6)	0 / 1 (0.0)	0 / 5 (0.0)	1 / 45 (2.2)
Rectal	2022	0 / 93 (0.0)	0 / 3 (0.0)	0 / 4 (0.0)	0 / 100 (0.0)
Rectal	2023	0 / 84 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 86 (0.0)
Rectal	2024	0 / 45 (0.0)	0 / 2 (0.0)	0 / 0 (0.0)	0 / 47 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 72 (0.0)	0 / 44 (0.0)	0 / 13 (0.0)	0 / 129 (0.0)
Genital	2023	0 / 71 (0.0)	0 / 37 (0.0)	0 / 5 (0.0)	0 / 113 (0.0)
Genital	2024	0 / 29 (0.0)	0 / 19 (0.0)	0 / 6 (0.0)	0 / 54 (0.0)
Pharyngeal	2022	0 / 58 (0.0)	0 / 3 (0.0)	0 / 7 (0.0)	0 / 68 (0.0)
Pharyngeal	2023	0 / 56 (0.0)	0 / 5 (0.0)	0 / 3 (0.0)	0 / 64 (0.0)
Pharyngeal	2024	0 / 39 (0.0)	0 / 1 (0.0)	0 / 5 (0.0)	0 / 45 (0.0)
Rectal	2022	0 / 93 (0.0)	0 / 3 (0.0)	0 / 4 (0.0)	0 / 100 (0.0)
Rectal	2023	0 / 84 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 86 (0.0)
Rectal	2024	0 / 45 (0.0)	0 / 2 (0.0)	0 / 0 (0.0)	0 / 47 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	13 / 72 (18.1)	1 / 44 (2.3)	0 / 13 (0.0)	14 / 129 (10.9)
Genital	2023	9 / 71 (12.7)	1 / 37 (2.7)	0 / 5 (0.0)	10 / 113 (8.8)
Genital	2024	3 / 29 (10.3)	1 / 19 (5.3)	0 / 6 (0.0)	4 / 54 (7.4)
Pharyngeal	2022	6 / 58 (10.3)	0 / 3 (0.0)	0 / 7 (0.0)	6 / 68 (8.8)
Pharyngeal	2023	8 / 56 (14.3)	0 / 5 (0.0)	0 / 3 (0.0)	8 / 64 (12.5)
Pharyngeal	2024	4 / 39 (10.3)	0 / 1 (0.0)	0 / 5 (0.0)	4 / 45 (8.9)
Rectal	2022	9 / 93 (9.7)	1 / 3 (33.3)	0 / 4 (0.0)	10 / 100 (10.0)
Rectal	2023	8 / 84 (9.5)	0 / 0 (0.0)	1 / 2 (50.0)	9 / 86 (10.5)
Rectal	2024	4 / 45 (8.9)	0 / 2 (0.0)	0 / 0 (0.0)	4 / 47 (8.5)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	24 / 72 (33.3)	16 / 44 (36.4)	6 / 13 (46.2)	46 / 129 (35.7)
Genital	2023	36 / 71 (50.7)	16 / 37 (43.2)	5 / 5 (100.0)	57 / 113 (50.4)
Genital	2024	19 / 29 (65.5)	12 / 19 (63.2)	3 / 6 (50.0)	34 / 54 (63.0)
Pharyngeal	2022	22 / 58 (37.9)	3 / 3 (100.0)	2 / 7 (28.6)	27 / 68 (39.7)
Pharyngeal	2023	28 / 56 (50.0)	3 / 5 (60.0)	3 / 3 (100.0)	34 / 64 (53.1)
Pharyngeal	2024	25 / 39 (64.1)	0 / 1 (0.0)	3 / 5 (60.0)	28 / 45 (62.2)
Rectal	2022	47 / 93 (50.5)	0 / 3 (0.0)	1 / 4 (25.0)	48 / 100 (48.0)
Rectal	2023	39 / 84 (46.4)	0 / 0 (0.0)	1 / 2 (50.0)	40 / 86 (46.5)
Rectal	2024	27 / 45 (60.0)	1 / 2 (50.0)	0 / 0 (0.0)	28 / 47 (59.6)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	7 (6.3)	28 (25.2)	24 (21.6)	23 (20.7)	9 (8.1)	6 (5.4)	5 (4.5)	2 (1.8)	2 (1.8)	3 (2.7)	2 (1.8)	111
Genital	Female	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	3 (23.1)	5 (38.5)	3 (23.1)	2 (15.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	13
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	0 (0.0)	73 (65.8)	0 (0.0)	6 (5.4)	6 (5.4)	15 (13.5)	11 (9.9)	111
Genital	Female	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	3 (23.1)	0 (0.0)	2 (15.4)	2 (15.4)	2 (15.4)	4 (30.8)	13
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	76	177	5	258
Genital	2023	45	112	5	162
Genital	2024	30	81	2	113
Pharyngeal	2022	6	0	0	6
Pharyngeal	2023	14	0	0	14
Pharyngeal	2024	0	0	0	0
Rectal	2022	34	0	0	34
Rectal	2023	33	0	1	34
Rectal	2024	11	0	0	11

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	202 (77.1)	50 (19.1)	6 (2.3)	4 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	262
Genital	2023	106 (65.0)	37 (22.7)	11 (6.7)	8 (4.9)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	163
Genital	2024	87 (77.0)	13 (11.5)	9 (8.0)	4 (3.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Pharyngeal	2022	5 (83.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	7 (50.0)	3 (21.4)	0 (0.0)	3 (21.4)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	24 (70.6)	5 (14.7)	3 (8.8)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	34
Rectal	2023	22 (62.9)	5 (14.3)	3 (8.6)	4 (11.4)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	35
Rectal	2024	8 (61.5)	1 (7.7)	3 (23.1)	1 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	13

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	184 (70.2)	65 (24.8)	12 (4.6)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	262
Genital	2023	101 (62.0)	47 (28.8)	14 (8.6)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	163
Genital	2024	68 (60.2)	36 (31.9)	8 (7.1)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Pharyngeal	2022	6 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	7 (50.0)	3 (21.4)	4 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	21 (61.8)	9 (26.5)	2 (5.9)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	34
Rectal	2023	19 (54.3)	9 (25.7)	6 (17.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.9)	35
Rectal	2024	7 (53.8)	3 (23.1)	3 (23.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	13

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	85 (32.4)	102 (38.9)	35 (13.4)	32 (12.2)	7 (2.7)	0 (0.0)	1 (0.4)	0 (0.0)	262
Genital	2023	34 (20.9)	77 (47.2)	13 (8.0)	23 (14.1)	6 (3.7)	1 (0.6)	8 (4.9)	1 (0.6)	163
Genital	2024	16 (14.2)	58 (51.3)	7 (6.2)	17 (15.0)	10 (8.8)	0 (0.0)	5 (4.4)	0 (0.0)	113
Pharyngeal	2022	0 (0.0)	3 (50.0)	2 (33.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	2 (14.3)	7 (50.0)	3 (21.4)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2024	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	10 (29.4)	12 (35.3)	6 (17.6)	4 (11.8)	1 (2.9)	1 (2.9)	0 (0.0)	0 (0.0)	34
Rectal	2023	3 (8.6)	19 (54.3)	3 (8.6)	8 (22.9)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	35
Rectal	2024	2 (15.4)	9 (69.2)	2 (15.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	13

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 76 (0.0)	0 / 177 (0.0)	0 / 5 (0.0)	0 / 258 (0.0)
Genital	2023	0 / 45 (0.0)	1 / 112 (0.9)	0 / 5 (0.0)	1 / 162 (0.6)
Genital	2024	0 / 30 (0.0)	0 / 81 (0.0)	0 / 2 (0.0)	0 / 113 (0.0)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	1 / 14 (7.1)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 14 (7.1)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	1 / 34 (2.9)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 34 (2.9)
Rectal	2023	1 / 33 (3.0)	0 / 0 (0.0)	0 / 1 (0.0)	1 / 34 (2.9)
Rectal	2024	0 / 11 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 11 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 76 (0.0)	0 / 177 (0.0)	0 / 5 (0.0)	0 / 258 (0.0)
Genital	2023	0 / 45 (0.0)	0 / 112 (0.0)	0 / 5 (0.0)	0 / 162 (0.0)
Genital	2024	0 / 30 (0.0)	0 / 81 (0.0)	0 / 2 (0.0)	0 / 113 (0.0)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	1 / 34 (2.9)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 34 (2.9)
Rectal	2023	1 / 33 (3.0)	0 / 0 (0.0)	0 / 1 (0.0)	1 / 34 (2.9)
Rectal	2024	0 / 11 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 11 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 76 (0.0)	8 / 177 (4.5)	0 / 5 (0.0)	8 / 258 (3.1)
Genital	2023	2 / 45 (4.4)	13 / 112 (11.6)	1 / 5 (20.0)	16 / 162 (9.9)
Genital	2024	2 / 30 (6.7)	13 / 81 (16.0)	0 / 2 (0.0)	15 / 113 (13.3)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	2 / 14 (14.3)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 14 (14.3)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	2 / 34 (5.9)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 34 (5.9)
Rectal	2023	2 / 33 (6.1)	0 / 0 (0.0)	0 / 1 (0.0)	2 / 34 (5.9)
Rectal	2024	0 / 11 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 11 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	35 / 76 (46.1)	58 / 177 (32.8)	0 / 5 (0.0)	93 / 258 (36.0)
Genital	2023	25 / 45 (55.6)	43 / 112 (38.4)	3 / 5 (60.0)	71 / 162 (43.8)
Genital	2024	14 / 30 (46.7)	23 / 81 (28.4)	2 / 2 (100.0)	39 / 113 (34.5)
Pharyngeal	2022	3 / 6 (50.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 6 (50.0)
Pharyngeal	2023	8 / 14 (57.1)	0 / 0 (0.0)	0 / 0 (0.0)	8 / 14 (57.1)
Pharyngeal	2024	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2022	16 / 34 (47.1)	0 / 0 (0.0)	0 / 0 (0.0)	16 / 34 (47.1)
Rectal	2023	14 / 33 (42.4)	0 / 0 (0.0)	1 / 1 (100.0)	15 / 34 (44.1)
Rectal	2024	6 / 11 (54.5)	0 / 0 (0.0)	0 / 0 (0.0)	6 / 11 (54.5)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	11 (6.5)	40 (23.5)	44 (25.9)	24 (14.1)	22 (12.9)	9 (5.3)	4 (2.4)	5 (2.9)	3 (1.8)	6 (3.5)	2 (1.2)	170
Genital	Female	2 (9.1)	8 (36.4)	4 (18.2)	3 (13.6)	3 (13.6)	0 (0.0)	1 (4.5)	1 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	Male	3 (5.4)	15 (26.8)	17 (30.4)	9 (16.1)	4 (7.1)	4 (7.1)	2 (3.6)	0 (0.0)	0 (0.0)	2 (3.6)	0 (0.0)	56
Pharyngeal	Female	1 (7.1)	4 (28.6)	3 (21.4)	3 (21.4)	1 (7.1)	0 (0.0)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	Male	3 (7.1)	7 (16.7)	10 (23.8)	11 (26.2)	3 (7.1)	2 (4.8)	1 (2.4)	1 (2.4)	4 (9.5)	0 (0.0)	0 (0.0)	42
Rectal	Female	0 (0.0)	0 (0.0)	1 (25.0)	1 (25.0)	1 (25.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	3 (1.8)	0 (0.0)	45 (26.5)	4 (2.4)	34 (20.0)	79 (46.5)	3 (1.8)	2 (1.2)	170
Genital	Female	0 (0.0)	0 (0.0)	3 (13.6)	0 (0.0)	7 (31.8)	12 (54.5)	0 (0.0)	0 (0.0)	22
Pharyngeal	Male	0 (0.0)	1 (1.8)	6 (10.7)	0 (0.0)	16 (28.6)	30 (53.6)	3 (5.4)	0 (0.0)	56
Pharyngeal	Female	0 (0.0)	0 (0.0)	2 (14.3)	0 (0.0)	7 (50.0)	5 (35.7)	0 (0.0)	0 (0.0)	14
Rectal	Male	1 (2.4)	1 (2.4)	2 (4.8)	0 (0.0)	13 (31.0)	24 (57.1)	1 (2.4)	0 (0.0)	42
Rectal	Female	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)	3 (75.0)	0 (0.0)	0 (0.0)	0 (0.0)	4

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	69	166	49	284
Genital	2023	91	155	46	292
Genital	2024	68	101	21	190
Pharyngeal	2022	45	19	34	98
Pharyngeal	2023	43	12	19	74
Pharyngeal	2024	47	9	14	70
Rectal	2022	66	0	5	71
Rectal	2023	72	1	4	77
Rectal	2024	42	0	4	46

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	197 (69.4)	72 (25.4)	7 (2.5)	6 (2.1)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	284
Genital	2023	216 (74.0)	56 (19.2)	9 (3.1)	11 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	292
Genital	2024	137 (71.4)	23 (12.0)	8 (4.2)	19 (9.9)	3 (1.6)	2 (1.0)	0 (0.0)	0 (0.0)	192
Pharyngeal	2022	73 (74.5)	21 (21.4)	2 (2.0)	2 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Pharyngeal	2023	46 (61.3)	12 (16.0)	9 (12.0)	8 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	75
Pharyngeal	2024	49 (70.0)	6 (8.6)	4 (5.7)	11 (15.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Rectal	2022	49 (69.0)	20 (28.2)	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	48 (62.3)	16 (20.8)	3 (3.9)	8 (10.4)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	77
Rectal	2024	32 (69.6)	4 (8.7)	2 (4.3)	7 (15.2)	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	46

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	192 (67.6)	83 (29.2)	7 (2.5)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	284
Genital	2023	194 (66.4)	77 (26.4)	18 (6.2)	3 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	292
Genital	2024	131 (68.2)	39 (20.3)	16 (8.3)	5 (2.6)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	192
Pharyngeal	2022	62 (63.3)	30 (30.6)	6 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Pharyngeal	2023	35 (46.7)	24 (32.0)	14 (18.7)	2 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	75
Pharyngeal	2024	42 (60.0)	22 (31.4)	6 (8.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Rectal	2022	49 (69.0)	20 (28.2)	2 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	42 (54.5)	25 (32.5)	5 (6.5)	5 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Rectal	2024	28 (60.9)	15 (32.6)	3 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	46

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	59 (20.8)	164 (57.7)	15 (5.3)	36 (12.7)	8 (2.8)	0 (0.0)	1 (0.4)	1 (0.4)	284
Genital	2023	39 (13.4)	158 (54.1)	29 (9.9)	47 (16.1)	16 (5.5)	0 (0.0)	0 (0.0)	3 (1.0)	292
Genital	2024	29 (15.1)	109 (56.8)	13 (6.8)	29 (15.1)	10 (5.2)	0 (0.0)	1 (0.5)	1 (0.5)	192
Pharyngeal	2022	20 (20.4)	52 (53.1)	6 (6.1)	12 (12.2)	4 (4.1)	1 (1.0)	2 (2.0)	1 (1.0)	98
Pharyngeal	2023	5 (6.7)	40 (53.3)	6 (8.0)	15 (20.0)	7 (9.3)	0 (0.0)	0 (0.0)	2 (2.7)	75
Pharyngeal	2024	5 (7.1)	42 (60.0)	3 (4.3)	10 (14.3)	8 (11.4)	1 (1.4)	0 (0.0)	1 (1.4)	70
Rectal	2022	7 (9.9)	44 (62.0)	2 (2.8)	15 (21.1)	3 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	7 (9.1)	49 (63.6)	8 (10.4)	9 (11.7)	4 (5.2)	0 (0.0)	0 (0.0)	0 (0.0)	77
Rectal	2024	3 (6.5)	30 (65.2)	4 (8.7)	6 (13.0)	3 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	46

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 69 (0.0)	2 / 166 (1.2)	0 / 49 (0.0)	2 / 284 (0.7)
Genital	2023	0 / 91 (0.0)	0 / 155 (0.0)	0 / 46 (0.0)	0 / 292 (0.0)
Genital	2024	3 / 68 (4.4)	1 / 101 (1.0)	1 / 21 (4.8)	5 / 190 (2.6)
Pharyngeal	2022	0 / 45 (0.0)	0 / 19 (0.0)	0 / 34 (0.0)	0 / 98 (0.0)
Pharyngeal	2023	0 / 43 (0.0)	0 / 12 (0.0)	0 / 19 (0.0)	0 / 74 (0.0)
Pharyngeal	2024	0 / 47 (0.0)	0 / 9 (0.0)	0 / 14 (0.0)	0 / 70 (0.0)
Rectal	2022	0 / 66 (0.0)	0 / 0 (0.0)	0 / 5 (0.0)	0 / 71 (0.0)
Rectal	2023	2 / 72 (2.8)	0 / 1 (0.0)	0 / 4 (0.0)	2 / 77 (2.6)
Rectal	2024	1 / 42 (2.4)	0 / 0 (0.0)	0 / 4 (0.0)	1 / 46 (2.2)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 69 (0.0)	0 / 166 (0.0)	0 / 49 (0.0)	0 / 284 (0.0)
Genital	2023	0 / 91 (0.0)	0 / 155 (0.0)	0 / 46 (0.0)	0 / 292 (0.0)
Genital	2024	1 / 68 (1.5)	0 / 101 (0.0)	0 / 21 (0.0)	1 / 190 (0.5)
Pharyngeal	2022	0 / 45 (0.0)	0 / 19 (0.0)	0 / 34 (0.0)	0 / 98 (0.0)
Pharyngeal	2023	0 / 43 (0.0)	0 / 12 (0.0)	0 / 19 (0.0)	0 / 74 (0.0)
Pharyngeal	2024	0 / 47 (0.0)	0 / 9 (0.0)	0 / 14 (0.0)	0 / 70 (0.0)
Rectal	2022	0 / 66 (0.0)	0 / 0 (0.0)	0 / 5 (0.0)	0 / 71 (0.0)
Rectal	2023	0 / 72 (0.0)	0 / 1 (0.0)	0 / 4 (0.0)	0 / 77 (0.0)
Rectal	2024	0 / 42 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)	0 / 46 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	3 / 69 (4.3)	5 / 166 (3.0)	2 / 49 (4.1)	10 / 284 (3.5)
Genital	2023	5 / 91 (5.5)	10 / 155 (6.5)	4 / 46 (8.7)	19 / 292 (6.5)
Genital	2024	4 / 68 (5.9)	7 / 101 (6.9)	1 / 21 (4.8)	12 / 190 (6.3)
Pharyngeal	2022	2 / 45 (4.4)	2 / 19 (10.5)	4 / 34 (11.8)	8 / 98 (8.2)
Pharyngeal	2023	4 / 43 (9.3)	4 / 12 (33.3)	1 / 19 (5.3)	9 / 74 (12.2)
Pharyngeal	2024	6 / 47 (12.8)	0 / 9 (0.0)	4 / 14 (28.6)	10 / 70 (14.3)
Rectal	2022	2 / 66 (3.0)	0 / 0 (0.0)	1 / 5 (20.0)	3 / 71 (4.2)
Rectal	2023	3 / 72 (4.2)	0 / 1 (0.0)	1 / 4 (25.0)	4 / 77 (5.2)
Rectal	2024	2 / 42 (4.8)	0 / 0 (0.0)	1 / 4 (25.0)	3 / 46 (6.5)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	26 / 69 (37.7)	38 / 166 (22.9)	15 / 49 (30.6)	79 / 284 (27.8)
Genital	2023	36 / 91 (39.6)	46 / 155 (29.7)	13 / 46 (28.3)	95 / 292 (32.5)
Genital	2024	32 / 68 (47.1)	33 / 101 (32.7)	7 / 21 (33.3)	72 / 190 (37.9)
Pharyngeal	2022	19 / 45 (42.2)	10 / 19 (52.6)	8 / 34 (23.5)	37 / 98 (37.8)
Pharyngeal	2023	24 / 43 (55.8)	5 / 12 (41.7)	7 / 19 (36.8)	36 / 74 (48.6)
Pharyngeal	2024	23 / 47 (48.9)	4 / 9 (44.4)	5 / 14 (35.7)	32 / 70 (45.7)
Rectal	2022	25 / 66 (37.9)	0 / 0 (0.0)	1 / 5 (20.0)	26 / 71 (36.6)
Rectal	2023	34 / 72 (47.2)	0 / 1 (0.0)	2 / 4 (50.0)	36 / 77 (46.8)
Rectal	2024	20 / 42 (47.6)	0 / 0 (0.0)	2 / 4 (50.0)	22 / 46 (47.8)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1-July 31, 2024

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0.0)	1 (5.3)	5 (26.3)	7 (36.8)	2 (10.5)	2 (10.5)	1 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)	19
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1-July 31, 2024

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0.0)	2 (10.5)	7 (36.8)	0 (0.0)	3 (15.8)	7 (36.8)	0 (0.0)	0 (0.0)	19
Genital	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	Male	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	1
Rectal	Female	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.

AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2022	7	11	0	18
Genital	2023	15	6	0	21
Genital	2024	12	7	0	19
Pharyngeal	2022	4	0	0	4
Pharyngeal	2023	2	0	1	3
Pharyngeal	2024	1	1	0	2
Rectal	2022	3	0	0	3
Rectal	2023	2	0	0	2
Rectal	2024	1	0	0	1

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2022	14 (77.8)	4 (22.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	13 (61.9)	2 (9.5)	4 (19.0)	1 (4.8)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21
Genital	2024	15 (75.0)	4 (20.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2022	1 (25.0)	1 (25.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	1 (33.3)	0 (0.0)	0 (0.0)	1 (33.3)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2024	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2022	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2022	11 (61.1)	7 (38.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	11 (52.4)	7 (33.3)	2 (9.5)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	21
Genital	2024	14 (70.0)	5 (25.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2022	1 (25.0)	2 (50.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	1 (33.3)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2024	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2022	2 (66.7)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2022	5 (27.8)	11 (61.1)	1 (5.6)	0 (0.0)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	2 (9.5)	9 (42.9)	3 (14.3)	6 (28.6)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21
Genital	2024	1 (5.0)	12 (60.0)	4 (20.0)	1 (5.0)	2 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2022	1 (25.0)	3 (75.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	0 (0.0)	0 (0.0)	1 (33.3)	1 (33.3)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2024	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2022	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2024	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 7 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 18 (0.0)
Genital	2023	0 / 15 (0.0)	1 / 6 (16.7)	0 / 0 (0.0)	1 / 21 (4.8)
Genital	2024	0 / 12 (0.0)	0 / 7 (0.0)	0 / 0 (0.0)	0 / 19 (0.0)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	1 / 1 (100.0)	1 / 3 (33.3)
Pharyngeal	2024	0 / 1 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2022	0 / 3 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 3 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 1 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC ≥ 0.25 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 7 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 18 (0.0)
Genital	2023	0 / 15 (0.0)	0 / 6 (0.0)	0 / 0 (0.0)	0 / 21 (0.0)
Genital	2024	0 / 12 (0.0)	0 / 7 (0.0)	0 / 0 (0.0)	0 / 19 (0.0)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 3 (0.0)
Pharyngeal	2024	0 / 1 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2022	0 / 3 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 3 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 1 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC ≥ 0.125 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	0 / 7 (0.0)	1 / 11 (9.1)	0 / 0 (0.0)	1 / 18 (5.6)
Genital	2023	1 / 15 (6.7)	0 / 6 (0.0)	0 / 0 (0.0)	1 / 21 (4.8)
Genital	2024	1 / 12 (8.3)	0 / 7 (0.0)	0 / 0 (0.0)	1 / 19 (5.3)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	1 / 1 (100.0)	1 / 3 (33.3)
Pharyngeal	2024	0 / 1 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2022	1 / 3 (33.3)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 3 (33.3)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2024	0 / 1 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance ≥ 2.0 $\mu\text{g/mL}$. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥ 2.0 $\mu\text{g/mL}$).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, January 1, 2022-July 31, 2024

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2022	5 / 7 (71.4)	7 / 11 (63.6)	0 / 0 (0.0)	12 / 18 (66.7)
Genital	2023	9 / 15 (60.0)	3 / 6 (50.0)	0 / 0 (0.0)	12 / 21 (57.1)
Genital	2024	5 / 12 (41.7)	2 / 7 (28.6)	0 / 0 (0.0)	7 / 19 (36.8)
Pharyngeal	2022	3 / 4 (75.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 4 (75.0)
Pharyngeal	2023	1 / 2 (50.0)	0 / 0 (0.0)	1 / 1 (100.0)	2 / 3 (66.7)
Pharyngeal	2024	0 / 1 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2022	2 / 3 (66.7)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 3 (66.7)
Rectal	2023	2 / 2 (100.0)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 2 (100.0)
Rectal	2024	0 / 1 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC ≥ 1.0 $\mu\text{g/mL}$.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.